HX-111

N/A

Report date: 2026/02/11 20:01:36

Base Information

Drug NameHX-111
Drug Alias NameHX-111HX111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 4
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHong KongMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHanx Biopharmaceuticals (Wuhan) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanx Biopharmaceuticals (Wuhan) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A